

Search for Correlation of CD8 T Cell Response to Epstein-Barr Virus with Clinical Status in Rheumatoid Arthritis: A 15 Month Followup Pilot Study

JEAN-MARIE BERTHELOT, XAVIER SAULQUIN, MARIANNE COSTE-BUREL, MARIE A. PEYRAT, KLARA ECHASSERIEAU, MARC BONNEVILLE, and ELISABETH HOUSSAINT

ABSTRACT. Objective. To assess in a longitudinal 15 month followup study the CD8 T cell response to immunodominant Epstein-Barr virus (EBV) antigens of 17 patients with rheumatoid arthritis (RA); and to seek an association between these responses and both clinical activity/severity of RA and a qualitative PCR for EBV in peripheral blood.

Methods. At each patient's visit every 3 months: (1) RA activity was assessed for Disease Activity Score (DAS-28); (2) a qualitative PCR for EBV was performed; (3) CD8 T cell response to EBV epitopes was screened in peripheral blood, using an autresentation assay of 13 EBV peptides previously identified as immunodominant targets in RA synovia. Activation of anti-EBV CD8 T cells was evaluated by measuring the release of tumor necrosis factor- α .

Results. The semiquantitative CD8 T cell response to EBV roughly paralleled RA clinical activity in only 4/17 patients. No clear association could be found between positive PCR for EBV (performed at least once in 10/17 patients) and RA activity/severity or fatigue. Reactivity was not qualitatively broader in samples where PCR for EBV proved positive, and most often focused on one or 2 EBV antigens. However, these antigens differed between patients, as did the magnitude of CD8 T cell response to immunodominant antigens at different timepoints for the same patient.

Conclusion. The CD8 T cell response to EBV paralleled clinical activity in only 4/17 patients. Our pilot study does not support the hypothesis that this CD8 response contributes to RA activity/flares, although the quantitative variations in the pattern of this reactivity over time confirmed that control of EBV manifestations was difficult in most patients with RA. (J Rheumatol 2003;30:1673-9)

Key Indexing Terms:

RHEUMATOID ARTHRITIS CD8 T CELLS EPSTEIN-BARR VIRUS LYMPHOCYTES

Epstein-Barr virus (EBV) has long been suspected to be involved in the pathogenesis of rheumatoid arthritis (RA), at least as a cofactor¹. This suspicion was raised by observation of an increased frequency and concentrations of antibodies against specific epitopes on EBV encoded EBNA1 (BKRF1) and EBNA3 (BERF1) antigens, and by the decreased ability of lymphocytes from patients with RA to limit outgrowth of autologous EBV infected lymphocytes¹. It was later recognized that RA was associated with HLA-DR alleles sharing a QK/RRAA motif also found within the EBV gp110 protein (BALF4)², a phenomenon suspected to contribute to the poor control of autologous EBV infected

lymphocytes. Recent reports indeed confirm that patients with RA have a decreased T cell response to the EBV gp110 (BALF4)³, a glycoprotein usually undetectable in virions but essential for EBV replication in human cells⁴⁻⁶. Although T cell recognition of other EBV proteins (like BZLF1) has been considered as more crucial to control EBV⁷, some investigators have put forward the hypothesis that this decreased response to BALF4 could account for the reactivation of EBV³ in B cells from RA bone marrow⁸ and/or synovium. This possibility would be in accord with recent reports of the presence of EBV genome in RA synovia, especially for patients with the QK/RRAA motif⁹, including fibroblast-like synoviocytes¹⁰ or lining cells at the top of villus lesions¹¹. Indeed, although humoral and CD8 T cell responses are probably involved in control of EBV infection¹², EBV reactivation seems to be mostly controlled by CD8 T cell responses¹³ (mainly lytic epitope-specific CD8 T cells¹⁴), in a quantitatively and qualitatively changing homeostasis between the virus and the immune system¹⁵. Extensive screening of the CD8 T cell responses in the synovial fluid of patients with RA showed that T cells specific for EBV epitopes were much enriched in their synovial fluid¹⁶, and were highly focused to a restricted set of immunodominant epitopes, primarily generated during

From the Rheumatology Unit, CHU Nantes; INSERM U463, Institut de Biologie; and Laboratory of Virology, CHU Nantes, Nantes, France.

Supported in part by the Association pour la Recherche sur la Polyarthrite (ARP), La Ligue Nationale contre le Cancer (LNCC), the Centre Hospitalier de Nantes, and by institutional grants from INSERM.

J.-M. Berthelot, MD, Rheumatology Unit, CHU Nantes; X. Saulquin, PhD; M.A. Peyrat; K. Echasserieau; M. Bonneville, PhD; E. Houssaint, PhD, INSERM U463, Institut de Biologie; M. Coste-Burel, MD, Laboratory of Virology, CHU Nantes.

Address reprint requests to Dr. J.-M. Berthelot, Service de Rhumatologie, Hôtel-Dieu, CHU Nantes, 44093, Nantes-Cedex 01, France.

E-mail: jeanmarie.berthelot@chu-nantes.fr

Submitted July 3, 2002; revision accepted January 8, 2003.

the early lytic cycle of EBV⁷, while the response to gp110 was by contrast often undetectable¹⁷⁻¹⁹. Transient reactivation of EBV (favored by a qualitative defect of CD4 and/or CD8 T cell responses toward some EBV critical epitopes) followed by delayed and excessive CD8 T cell responses (toward the same or other EBV critical epitopes) could contribute to RA flares and/or global level of RA activity, in RA and in other disorders with B cell autoimmunity. To investigate this hypothesis, we prospectively gathered clinical and biological data every 3 months from 17 patients with RA over a 15 month period to seek for any correlation between RA activity and (1) CD8 T cell responses to immunodominant EBV peptides in peripheral blood, and (2) the presence of EBV confirmed by polymerase chain reaction (PCR) in peripheral blood. As well we investigated the relationship between EBV resurgence in blood and the qualitative profile of CD8 T cell responses of those 17 patients.

MATERIALS AND METHODS

Patients. The 17 patients were prospectively, randomly, and consecutively selected from RA outpatients followed in our institution. All gave informed consent for that study, which had been approved by the local ethics committee. These 17 patients had typical RA²⁰ with no overlap with other connective tissue disorders or conditions associated with immunosuppression (except one 70-year-old woman with idiopathic thrombocytopenia treated with low dose hydroxyurea). Patients' mean age was 57 ± 16 years (range 26–80). Duration of RA for the group was 11.6 ± 8.2 years (range 2–28). All had positive serology for EBV infection, but none had been diagnosed with infectious mononucleosis and/or had previously had severe sore throat and/or recurrent pharyngitis. All were currently treated with disease modifying antirheumatic drugs, including etanercept in one case (Patient 17), parenteral gold salts in 2 cases, sulfasalazine in 2, and low dose

methotrexate (7.5–15 mg weekly) in 12 cases; these prescriptions remained unchanged during the whole study period; 10/17 patients were taking oral steroids. The clinical activity of these patients was very variable at different timepoints, and their overall severity was also quite different (Figure 1, Table 1): the median Disease Activity Score (DAS28) values for the 6 visits ranged from 2.61 ± 0.50 (Patient 12) to 5.97 ± 1.24 (Patient 6). HLA class I genotyping (Centre Régional de Transfusion Sanguine, Nantes, France) was as described²¹. Results of this genotyping for each patient are given in Table 1.

Assessment of disease activity. At each visit, the following data were collected for each patient: DAS28 score (a composite index of both clinical and biological activity²²), morning stiffness, pain level on an analog scale of 0 (no pain) to 10 (maximal pain), fatigue level on an analog scale of 0 (no fatigue) to 10 (maximal fatigue), and C-reactive protein (CRP) value (mg/l). A DAS28 value > 3.2 indicates active RA.

PCR for the detection of EBV. DNA samples. Peripheral blood samples (7 ml) were collected into EDTA. Peripheral blood mononuclear cells were isolated by Ficoll-hypaque centrifugation and a final suspension of 10^7 cells/ml in phosphate buffered saline was performed. Two aliquots were stored at -20°C until the amplification procedure.

PCR analysis. One aliquot was used as the DNA template for qualitative detection of EBV DNA by PCR. Before amplification, cells were boiled and centrifuged 10 min at 8000 g. A 121 base pair (bp) fragment located in the unique BamH1C region was amplified using the 2 primers EBV1 (5' GACAACCTCGGCCGTGATGGA 3') (position 4010–4029) and EBV2 (5' TGAAGTTGGAGGCGGACGAG 3') (position 4130–4111). Amplification reactions were performed in a final volume of 25 μl with deoxyribonucleotides at 200 μM each, 1.5 mM MgCl_2 , 1 μM of each primer, 2.5 units Taq DNA polymerase (Pharmacia, Guyancourt, France), and 3 μl of DNA sample. The amplification mixture was overlaid with mineral oil, and amplifications were carried out on a PCR processor (Thermal Reactor, Hybaid, Middlesex, UK). After the first denaturation at 95°C for 7 min, PCR was carried out for a total of 35 cycles (denaturation 30 s at 94°C , annealing 30 s at 60°C , extension 1 min at 72°C) with a final extension 5 min at 72°C . The PCR products were hybridized with a biotinylated




Figure 1. Vertical lines represent fluctuations of DAS28 scores of 17 patients during the 15 months' followup (one visit every 3 months) (upper values: visits during which RA clinical activity was highest; lower values: lowest clinical activity). Arrowheads indicate a positive PCR for EBV.

Table 1. Patients' CD8 T cell responses to EBV peptides and PCR for EBV at each visit. The amount of TNF released in the responding T cell lines was estimated by the WEHI 164 cytotoxic assay²⁴: release of TNF < 1 µg/ml was considered negative, 1–10 µg/ml (+), 10–20 µg/ml (++), 20–50 µg/ml (+++), 50–200 µg/ml (++++), > 200 µg/ml (+++++). In rare cases (“?”) background noise prevented evaluation of TNF release. Only positive PCR results for EBV are given: remaining results were negative.

| Patient/Phenotype | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 |
|----------------------|--|---|--|--|---|---|
| 1 A11,B8,B27 | ENBA3B/A11 + DAS28 = 5.63 | EBNA3B/A11 + DAS28 = 5.46 | – DAS28 = 4.51 | BRLF1/A2 + DAS28 = 3.50 | – DAS28 = 2.97 | – DAS28 = 5.92 |
| 2 A1,B8,B55 | – DAS28 = 4.37 | BZLF1/B8 +++ DAS28 = 5.55 | BZLF1/B8 ++ DAS28 = 4.10 | BZLF1/B8 + (PCR EBV+) DAS28 = 2.90 | BZLF1/B8 ++ DAS28 = 4.11 | BZLF1/B8 ++ (PCR EBV +) DAS28 = 3.74 |
| 3 A2,A3,B7,B15 | – DAS28 = 6.95 | – DAS28 = 4.50 | – (PCR EBV+) DAS28 = 4.82 | – DAS28 = 5.05 | – DAS28 = 3.23 | – DAS28 = 3.43 |
| 4 A2,A11,B15,B55 | EBNA3B/A11 ++++ DAS28 = 5.09 | – DAS28 = 3.61 | – DAS28 = 3.70 | – DAS28 = 3.90 | – DAS28 = 2.99 | EBNA3B/A11 ++ BMLF1/A2 + DAS28 = 3.34 |
| 5 A2,B44,B49 | BMLF1/A2 ++++ (PCR EBV+) DAS28 = 3.89 | BMLF1/A2 ++++ DAS28 = 3.10 | BMLF1/A2 +++ BMRF1A2 +++++ LMP2/A2 +++++ BZLF1/B8 +++++ EBNA3A/A2 ++++ EBNA3C/A2 ++ BRLF1/A2 ++ DAS28 = 4.55 | – DAS28 = 2.71 | BMLF1/A2 +++ LMP2/A2 + BRLF1/A2 + DAS28 = 2.28 | BMLF1/A2 + DAS28 = 5.07 |
| 6 A1,A2,B37,B44 | BMLF1/A2 + DAS28 = 5.74 | BMLF1/A2 +++++ BRLF1/A2 +++++ LMP2/A2 +++++ EBNA3A/A2 ++++ EBNA3C/A2 +++ DAS28 = 7.62 | BRLF1/A2 +++ DAS28 = 7.30 | LMP2/A2 +/- DAS28 = 4.40 | – DAS28 = 5.54 | BMLF1/A2 ++ DAS28 = 5.26 |
| 7 A2,A29,B44,B50 | ? DAS28 = 6.56 | BZLF1/B18 +++ DAS28 = 5.63 | ? DAS28 = 6.10 | – (PCR EBV +) DAS28 = 6.72 | – DAS28 = 4.46 | – DAS28 = 3.11 |
| 8 A2,B51,B55 | – DAS28 = 3.76 | – DAS28 = 3.55 | – (PCR EBV+) DAS28 = 3.30 | – DAS28 = 3.30 | – DAS28 = 3.32 | – DAS28 = 3.14 |
| 9 A1,A3,B7,B8 | – DAS28 = 3.68 | – DAS28 = 4.50 | – DAS28 = 3.11 | – DAS28 = 3.20 | – DAS28 = 3.07 | – DAS28 = 2.92 |
| 10 A2,A31,B35,B40 | BZLF1/B35 + DAS28 = 4.20 | BZLF1/B35 ++++ DAS28 = 3.65 | BZLF1/B35 + BMLF1/A2 + (PCR EBV+) DAS28 = 2.99 | – (PCR EBV+) DAS28 = 3.35 | BZLF1/B35 + DAS28 = 3.68 | BZLF1/B35 +/- DAS28 = 4.07 |
| 11 A1,A3,B8,B44 | – DAS28 = 4.86 | BZLF1/B8 +++ (PCR EBV +) DAS28 = 4.62 | BZLF1/B8 + DAS28 = 6.05 | BZLF1/B8 + DAS28 = 4.07 | BZLF1/B8 + DAS28 = 5.07 | BZLF1/B8 + DAS28 = 5.37 |
| 12 A2,A24,B39,B40 | – DAS28 = 3.51 | BMLF1/A2 ++ BZLF1/B8 +++++ (PCR EBV +) DAS28 = 2.38 | ? DAS28 = 2.30 | LMP2/B40 + DAS28 = 2.75 | BMLF1/A2 + DAS28 = 2.07 | BMLF1/A2 + BZLF1/B8 + BZLF1/B40 +++++ DAS28 = 2.65 |
| 13 A2,A11,B35,B53 | BRLF1/A2 + DAS28 = 5.72 | BRLF1/A2 + (PCR EBV +) DAS28 = 4.13 | – (PCR EBV +) DAS28 = 5.12 | – DAS28 = 5,4 | – (PCR EBV +) DAS28 = 5,67 | – DAS28 = 7.55 |
| 14 A2,B15,B49 | – DAS28 = 3.93 | – DAS28 = 2.80 | BRLF1/A2 + DAS28 = 4.61 | BMLF1/A2 + DAS28 = 5.64 | BMLF1/A2 + DAS28 = 5.88 | – DAS28 = 5.35 |
| 15 A1,A2,B7,B18 | – DAS28 = 5.39 | – DAS28 = 6.02 | – DAS28 = 4.70 | – (PCR EBV +) DAS28 = 6.61 | – DAS28 = 4.20 | – DAS28 = 2.27 |
| 16 A2,A24,B35,B40 | – DAS28 = 4.11 | – DAS28 = 3.06 | BMLF1/A2 +/- BRLF1/A2 + DAS28 = 3.40 | LMP2/B40 + DAS28 = 4.82 | LMP2/B40+ DAS28 = 4.62 | LMP2/B40+++ LMP2/A2 + DAS28 = 4.90 |
| 17 A2,A32,B35,B44 | BZLF1/B35 +++++ BMLF1/A2 + LMP2/A2 + DAS28 = 6.04 | BZLF1/B35 ++ BMLF1/A2 + DAS28 = 4.93 | BZLF1/B35 + LMP2/A2 +/- DAS28 = 4.70 | BZLF1/B35 + DAS28 = 4.35 | BZLF1/B35 +++ BMLF1/A2 + DAS28 = 3.89 | ? DAS28 = 3.02 |

internal specific oligonucleotide probe (5' TGGCCTGGGCGTGAAGCT-GACCTTTGGCTCGGCCTCTCT 3') (position 4060–4097) using the microtiter plate hybridization assay (ETI-K DEIA, Sorin Biomedica, Saluggia, Italy). To evaluate the sensitivity of our PCR, serial fold-dilutions of the Burkitt's lymphoma cell line Namalwa (2 EBV copies per cell) were prepared and amplified by PCR. It was possible to score the hybridization signal from 2 EBV copies.

T cell lines. Samples of peripheral blood were taken from the 17 RA patients. Mononuclear cells were isolated by Ficoll/Hypaque density gradient centrifugation. Peripheral blood lymphocytes were maintained in RPMI-1640 supplemented with 10% pooled human serum, 1 mM L-glutamine, and recombinant interleukin 2 (IL-2; 150 IU/ml), hereafter referred to as IL-2 supplemented culture medium (IL-2/CM). Lymphocytes were expanded *in vitro* in IL-2/CM supplemented with purified phytohemagglutinin (leukoagglutinin, 0.5 µg/ml) and irradiated (30 Gy) allogeneic feeder cells (peripheral blood and EBV transformed B lymphoblastoid cells at a 10/1 ratio) as described^{18,19}. Cells were maintained for 3 to 4 weeks without restimulation prior to functional analysis.

Peptides. Peptides were all synthesized commercially by Genosys (The Woodlands, TX, USA) or Chiron (Chiron Mimotopes Corp., Victoria, Australia). Peptide stock solutions (20 ng/ml in DMSO) were diluted first to 2 ng/ml in acetic acid (1%) and second to the final concentration in RPMI-1640 culture medium. Characterization of EBV epitopes recognized by polyclonal T cells was achieved in an autresentation assay by assaying the ability of a large set of peptides, previously characterized as dominant peptides for the CD8 T cells' response to EBV²³, to trigger tumor necrosis factor (TNF-α) release by responding T cell lines. The following CD8 T cell epitopes were screened systematically, whatever the HLA alleles of the donor: BMLF1²⁵⁹⁻²⁶⁷/A2, BMRF1²⁰⁸⁻²¹⁶/A2, BRLF1¹⁰⁰⁻¹²²/A2, EBNA3A⁵⁹⁶⁻⁶⁰⁴/A2, EBNA3C²⁸⁴⁻²⁹³/A2, LMP2³²⁹⁻³³⁷/A2, LMP2⁴²⁶⁻⁴³⁴/A2, EBNA3B³⁹⁹⁻⁴⁰⁸/A11, LMP2²⁰⁰⁻²⁰⁸/B4001, BZLF1¹⁹⁰⁻¹⁹⁷/B8, BZLF1¹⁷²⁻¹⁸³/B18, and BZLF1⁵⁴⁻⁶⁴/B35.




TNF assays. Production of TNF-α by activated lymphocytes was estimated in an autresentation assay. To trigger TNF-α release by responding T cells, 3 × 10⁴ polyclonal T cells were incubated for 5 h with individual peptide at 10 µM concentration, and the amount of TNF released in the supernatant was estimated by the WEHI 164 cytotoxic assay²⁴.

Expression of results. Results for CD8 T cell response to EBV are expressed qualitatively (Table 1) and by a semiquantitative method (Figures 2 to 4): release of TNF < 1 µg/ml was considered negative, between 1 and 10 µg/ml was denoted positive (+), with 10–20 µg/ml (++), 20–50 µg/ml (+++), 50–200 µg/ml (+++), and > 200 µg/ml (+++). In rare cases (designated “?” in Table 1) background noise prevented a correct evaluation of TNF release by cytotoxic T lymphocytes (CTL). For semiquantitative evaluation of the magnitude of TNF release on a 0 to 6 scale (Figures 2 to 4), the value of the stronger response was considered (i.e., a score of 4 for a sample with CTL release of magnitude ++++), except when 2 or more specificities gave similar levels of response: in that event the superior level was recorded (i.e., 2 scores of 3 for different peptides led to a final score of 4).

RESULTS

Clinical and biological activity over the 15 month period. DAS28 scores for each of the 17 patients during the 15 month followup appear in Figure 1. It had previously been defined that a 0.6 variation of the score was clinically significant. A variation of DAS28 ≥ 0.6 was noted between extreme values for 15/17 patients during the followup period.

PCR for EBV in peripheral blood. PCR was positive on one sample or more in 10/17 patients, Patients 2, 3, 5, 7, 8, 10, 11, 12, 13, and 15, although positive result was noted on



Figures 2 to 4. Three patients' DAS28 values (solid lines) and CD8 T cell responses to EBV peptides (semiquantitative scale from 0 to 6; broken lines). Data are shown for one of the 4 patients with a parallel between CD8 T cell response and clinical activity (Figure 2, Patient 2). In contrast, one patient had a burst of CD8 T cell response despite stable RA activity (Figure 3, Patient 10); and one patient had a poor CD8 T cell response with high RA activity (Figure 4, Patient 7).

only one occasion in 7 of these 10 cases. There were no differences in DAS28 (Figure 1, Table 2), semiquantitative evaluation of CD8 T cell response to EBV (Tables 1 and 3), fatigue (Table 4), CRP (Table 5), and broadness of CD8 T cell responses to EBV epitopes (Table 1) between patients with negative PCR and patients with positive PCR.

CD8 T cell responses to EBV peptides: qualitative results. CD8 T cell responses to EBV assayed by TNF-α production were consistently directed toward an immunodominant antigen in 11/17 cases (Table 1): BZLF1 (Patients 2, 10, 11, 17), BMLF1 (Patients 5, 6, 12, 14), BRLF1 (Patient 13), LMP2 (Patient 16), and EBNA3B (Patient 4). However, for

Table 2. DAS28 results (mean \pm SD) at each visit, comparing patients with positive/negative PCR result for EBV during the 15 month followup.

| | Visit1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 |
|------|---------------|---------------|---------------|---------------|---------------|---------------|
| EBV+ | 4.9 \pm 1.2 | 4.3 \pm 1.2 | 4.4 \pm 1.2 | 4.3 \pm 1.6 | 3.8 \pm 1.1 | 3.7 \pm 1.0 |
| EBV- | 4.9 \pm 1.0 | 4.6 \pm 1.7 | 4.5 \pm 1.4 | 4.3 \pm 0.8 | 4.1 \pm 1.2 | 4.6 \pm 1.3 |

Table 3. Semiquantitative evaluation of CD8 T cell response (mean \pm SD) to EBV immunodominant peptides screened at each visit, comparing patients with positive/negative PCR result for EBV during the 15 month followup.

| | Visit1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 |
|------|---------------|---------------|---------------|---------------|---------------|---------------|
| EBV+ | 0.7 \pm 1.3 | 2.3 \pm 1.9 | 1.8 \pm 2.2 | 0.3 \pm 0.5 | 0.8 \pm 1.0 | 0.7 \pm 0.8 |
| EBV- | 1.4 \pm 1.8 | 1.3 \pm 2.2 | 0.9 \pm 1.0 | 0.7 \pm 0.5 | 0.7 \pm 1.1 | 1.2 \pm 1.3 |

Table 4. Fatigue scores (mean \pm SD) [analog scale from 0 (no fatigue) to 100 (extreme fatigue)] at each visit, comparing patients with positive/negative PCR result for EBV during the 15 month followup.

| | Visit1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 |
|------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| EBV+ | 45.0 \pm 25.3 | 29.2 \pm 20.1 | 35.4 \pm 26.6 | 43.9 \pm 28.9 | 29.8 \pm 24.8 | 31.8 \pm 28.9 |
| EBV- | 45.8 \pm 17.1 | 37.1 \pm 22.8 | 40.3 \pm 19.6 | 35.5 \pm 23.9 | 29.1 \pm 30.0 | 20.2 \pm 16.6 |

Table 5. CRP (mg/l, mean \pm SD) at each visit, comparing patients with positive/negative PCR result for EBV during the 15 month followup.

| | Visit1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 |
|------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| EBV+ | 20.9 \pm 16.9 | 12.8 \pm 9.8 | 14.9 \pm 18.1 | 23.4 \pm 25.0 | 12.0 \pm 6.6 | 5.6 \pm 2.9 |
| EBV- | 29.9 \pm 30.7 | 26.6 \pm 29.3 | 29.6 \pm 35.2 | 19.6 \pm 16.5 | 14.6 \pm 14.4 | 30.8 \pm 37.5 |

most patients, other antigens could elicit a transient and even stronger CD8 T cell response. The broadness of the CD8 T cell response seemed to be no more associated with clinical activity of RA than its magnitude. No association could be found between the broadness response and a positive PCR for EBV on the same sample (Table 1): for instance, PCR remained negative for the 2 samples showing the broader response (visit 3/Patient 5 and visit 2/Patient 6) and was conversely positive in other samples with a seemingly narrow and/or poor CD8 T cell response (Patients 3, 7, 8, 13, 15).

CD8 T cell response to EBV peptides. Semiquantitative results. A striking parallel between clinical activity (assessed by DAS28 scores) and semiquantitative assessment of the CD8 T cell responses (assessed on the magnitude of TNF- α release) was noticed in Patients 2, 6, 14, and 17 (Figure 2, Patient 2). In other patients, either no relationship was determined (Patients 1, 3, 4, 5, 8, 10, 11, 12, 16), including some patients with a burst of CD8 T cell response not associated with clinical flare (Patients 10 and 12) (Figure 3, Patient 10), or the lack of identifiable response to EBV antigens precluded definitive conclusions (Patients 7, 9, 13, 15) (Figure 4, Patient 7). Similar observations were

made for CRP and fatigue and the CD8 T cell response to EBV (data not shown).

DISCUSSION

The first aim of this longitudinal pilot study was to look for a correlation between the clinical activity/severity of 17 patients with RA regularly assessed over a 15 month period and both the CD8 T cell response to EBV immunodominant epitopes in patients' peripheral blood and the resurgence of EBV at the same time. We did observe a striking parallel between clinical activity and CD8 T cell response in some patients, suggesting that CD8 T cell response to EBV could sustain the inflammatory process and/or RA itself. However, this was true for a minor subset of patients (4/17). This would be in accord with the hypothesis that RA is probably more a syndrome than a disease, i.e., an abnormal response to EBV (poor initial control, followed by excessive response) perhaps driving the disease process in only a minority of cases. This assumption would also be in line with early results of research into the EBV genome in RA synovia, which proved inconsistently positive; however, this research became much more successful in recent investigations using more sensitive methods, with results of 6%

(2/31)²⁵, 19% (7/37)²⁶, 20% (1/5)²⁷, 24% (8/34)¹¹, 30%²⁸, 35% (29/84)⁹, 47% (15/32)²⁹, and 91% (10/11)³⁰. Similarly, mRNA EBV transcripts have been more rarely detected by *in situ* hybridization [8% (EBER 1 and 2)²⁸, 16% (5/32) (EBER1)²⁹, and 24% (EBER1)¹¹] than by more sensitive RT-PCR for EBER1³⁰.

The lack of relationship between CD8 T cell response and clinical activity of RA in other patients could be ascribed either to the fact that CD8 T cell response to EBV plays no role in the pathogenesis of RA, or to technical limitations. In this respect, and for ethical reasons, only peripheral blood samples were taken (every 3 months) over the 15 month study period: a closer relationship between CD8 T cell response and RA activity might have been observed using synovial biopsies instead of peripheral blood.

The lack of relationship between the PCR results and CD8 T cell responses (Table 1) might be ascribed to the PCR technique we used, which analyzed roughly 30,000 peripheral blood mononuclear cells per reaction, thus offering a higher cutoff than in other studies using more sensitive techniques^{11,28}. However, it could also be partly explained by the lag time between EBV reactivation and in the occurrence of maximal CD8 T cell responses. Similarly, a lag between EBV resurgence and RA flares might also account for the negative PCR results during most RA flares, even in those patients for whom CD8 T cell responses were roughly parallel to RA clinical activity (Table 1). However, our overall results support a limited role for EBV in the pathogenesis of RA in most patients studied.

The second aim of the study was to look for a relationship between EBV resurgence in blood and the qualitative profile of CD8 T cell responses to EBV for the 17 patients. Recent longitudinal data on dynamics of antigen-specific CD8 cytotoxic T lymphocytes following primary EBV infection led to the observation that the protracted illness in one patient was associated with a narrowly focused response, while in contrast a broad T cell reactivity to multiple epitopes was noted in healthy virus carriers or for a patient who rapidly recovered from an acute infectious mononucleosis³¹. As the overall strength of cytolytic activity was greater in the patient who could not clear the EBV infection, this led to the hypothesis that the broadness of CD8 T cell responses is of greater importance than its magnitude to achieve good control of EBV, at least for primary infection. This could still be true later. Indeed, several reports have described that long after the primary infection, although CD8 T cell responses to EBV were still highly focused to a restricted set of early lytic proteins (and mainly BZLF1, BRLF1, and BMLF1; 42/342 tested EBV/HLA combinations in a recent report²³), most individuals had CTL responses to more than one EBV antigen^{7,19}, including weaker responses to some latent EBV proteins, namely EBNA3A, 3B, and 3C and LMP2 in 10 to 20% of patients. In those studies, the reactivity patterns were similar

for CD8 T cells from inflammatory sites and CD8 T cells from peripheral blood of longterm virus carriers free of autoimmune disorders⁷. We made similar observations, as most CD8 T cells from our patients responded to several EBV epitopes, including a dominant antigen (Table 1). However, for individual patients, we noted striking modifications of the pattern of response from the same patient at different timepoints, both qualitatively (Table 1) and semi-quantitatively (Figure 3). As no controls from healthy subjects or other chronic inflammatory processes were used, this could lead to the hypothesis that fluctuations of CD8 T cell response patterns are related to the poorer control of EBV previously described in RA. Our results strengthen observations of a permanently changing homeostasis between virus and immune system, at both quantitative and qualitative levels^{14,15}, which deserves further study.

Investigations would be even more instructive if CD4 T cell and NK responses were screened simultaneously with CD8 T cell responses. Indeed, assistance from CD4 T cells might be important for maintaining CD8 T cell memory³² and maturing CD8 T cell function³³, and might directly inhibit the proliferation of EBV infected B cells³⁴. Although CD4 T cell responses to EBV have been poorly analyzed to date, hampered by the small size of the CD4 compartment, it would be pertinent to determine the level of T cell response to EBV epitopes according to HLA-DR antigens and/or to the expression of the shared epitope.

In the absence of proof of a relationship between CD4 T cell responses to EBV and RA activity, our longitudinal screening of CD8 T cell responses to immunodominant EBV epitopes does not provide evidence that an excessive and delayed CD8 T cell response to EBV plays a significant part in most RA flares. However, our findings suggest a poor control of EBV infection (similar to that observed in systemic lupus erythematosus³⁵), as recently ascribed by Takei, *et al*³⁶ to low expression of signaling lymphocytic-activation molecule-associated protein (SAP) in peripheral leukocytes or T cells of patients with RA. Indeed, SAP functions as a regulator of a signal transduction pathway initiated by the molecule 2B4 (expressed on NK cells and a subset of CD8 T cells), which plays a leading role in the ability of NK cells to lyse EBV infected cells³⁶. Thus, as also described in X-linked lymphoproliferative syndromes (where mutations of the SAP gene have been identified), dysfunction of 2B4/SAP induced signal transduction pathways may be responsible for the ineffective T cell or NK cell response in sustaining the elimination of EBV infected cells in many patients with RA³⁶.

REFERENCES

1. Fox RI, Luppi M, Pisa P, Khang HI. Potential role of Epstein-Barr virus in Sjogren's syndrome and rheumatoid arthritis. *J Rheumatol* 1992;19 Suppl 32:18-24.
2. Roudier J, Petersen J, Rhodes GH, Luka J, Carson DA. Susceptibility to rheumatoid arthritis maps to a T-cell epitope

- shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. *Proc Natl Acad Sci USA* 1989;86:104-8.
3. Toussirot E, Auger I, Roudier C, et al. HLA-DR polymorphism influences T-cell precursor frequencies to Epstein-Barr virus gp110: implications for the association of HLA-DR antigens with rheumatoid arthritis. *Tissue Antigens* 1999;54:146-52.
 4. Herrold RE, Marchini A, Fruehling S, Longnecker R. Glycoprotein 110, the Epstein-Barr virus homolog of herpes simplex virus glycoprotein B, is essential for Epstein-Barr virus replication in vivo. *J Virol* 1996;70:2049-54.
 5. Lee SK, Longnecker R. The Epstein-Barr virus glycoprotein 110 carboxy-terminal tail domain is essential for lytic virus replication. *J Virol* 1997;71:4092-7.
 6. Papworth MA, Van Dijk AA, Benyon GR, Allen TD, Arrand JR, Mackett M. The processing, transport and heterologous expression of Epstein-Barr virus gp110. *J Gen Virol* 1997;78:2179-89.
 7. Houssaint E, Saulquin X, Scotet E, Bonneville M. Immunodominant CD8 T cell response to Epstein-Barr virus. *Biomed Pharmacother* 2001;55:373-80.
 8. Berthelot JM, Bataille R, Maugars Y, Prost A. Rheumatoid arthritis as a bone marrow disorder. *Semin Arthritis Rheum* 1996;26:505-14.
 9. Saal JG, Krimmel M, Steidle M, et al. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. *Arthritis Rheum* 1997;42:1485-96.
 10. Koide J, Takada K, Sugiura M, et al. Spontaneous establishment of an Epstein-Barr virus-infected fibroblast line from the synovial tissue of a rheumatoid arthritis patient. *J Virol* 1997;71:2478-81.
 11. Takei M, Mitamura K, Fujiwara S, et al. Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients. *Int Immunol* 1997;9:739-43.
 12. Hiraki A, Fujii N, Masuda K, Ikeda K, Tanimoto M. Genetics of Epstein-Barr virus infection. *Biomed Pharmacother* 2001;55:369-72.
 13. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. *Ann Oncol* 1998;9 Suppl 5:S129-32.
 14. Hislop AD, Anells NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. *J Exp Med* 2002;195:893-905.
 15. Babcock GJ, Hochberg D, Thorley-Lawson DA. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. *Immunity* 2000;13:497-506.
 16. Fazou C, Yang H, McMichael AJ, Callan MFC. Epitope specificity of clonally expanded populations of CD8 T cells found within the joints of patients with inflammatory arthritis. *Arthritis Rheum* 2001;44:2038-45.
 17. David-Ameline J, Lim A, Davodeau F, et al. Selection of T cells reactive against autologous B lymphoblastoid cells during chronic rheumatoid arthritis. *J Immunol* 1996;157:154-64.
 18. Scotet E, David-Ameline J, Peyrat MA, et al. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. *J Exp Med* 1996;184:1791-800.
 19. Scotet E, Peyrat MA, Saulquin X, et al. Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. *Eur J Immunol* 1999;29:973-85.
 20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
 21. Buyse I, Decorte R, Baens M, et al. Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization. *Tissue Antigens* 1993;41:1-14.
 22. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44-8.
 23. Saulquin X, Ibisch C, Peyrat MA, et al. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. *Eur J Immunol* 2000;30:2531-9.
 24. Espevik T, Nissen-Meyer JA. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. *J Immunol Methods* 1986;95:99-105.
 25. Mousavi-Jazi M, Bostrom L, Lovmark C, Linde A, Brytting M, Sundqvist VA. Infrequent detection of cytomegalovirus and Epstein-Barr virus DNA in synovial membrane of patients with rheumatoid arthritis. *J Rheumatol* 1998;25:623-8.
 26. Niedobitek G, Lisner R, Swoboda B, et al. Lack of evidence for an involvement of Epstein-Barr virus infection of synovial membranes in the pathogenesis of rheumatoid arthritis. *Arthritis Rheum* 2000;43:151-4.
 27. Brousset P. Lack of Epstein-Barr virus infection of synovial membranes in patients with rheumatoid arthritis [letter]. *Arthritis Rheum* 2000;43:2614.
 28. Blaschke S, Schwarz G, Moneke D, Binder L, Muller G, Reuss-Borst M. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. *J Rheumatol* 2000;27:866-73.
 29. Takeda T, Mizugaki Y, Matsubara L, Imai S, Koike T, Takada K. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. *Arthritis Rheum* 2000;43:1218-25.
 30. Edinger JW, Bonneville M, Scotet E, Houssaint E, Schumacher HR, Posnett DN. EBV gene expression not altered in rheumatoid synovia despite the presence of EBV antigen-specific cell clones. *J Immunol* 1999;162:3694-701.
 31. Bharadwaj M, Burrows SR, Burrows JM, Moss DJ, Catalina M, Khanna R. Longitudinal dynamics of antigen-specific CD8+ cytotoxic T lymphocytes following primary Epstein-Barr virus infection. *Blood* 2001;98:2588-9.
 32. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte response. *J Exp Med* 1998;182:2199-204.
 33. Zajac AJ, Blattlan JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. *J Exp Med* 1998;188:2205-13.
 34. Nikiforow S, Bottomly K, Miller G. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. *J Virol* 2001;75:3740-52.
 35. Gross AJ, Thorley-Lawson DA. High numbers of Epstein-Barr virus infected B-lymphocytes in the peripheral blood of patients with systemic lupus erythematosus [abstract]. *Arthritis Rheum* 2001;44 Suppl:2952.
 36. Takei M, Ishiwata T, Milamura K, et al. Decreased expression of signalling lymphocytic-activation molecule-associated protein (SAP) transcripts in T cell from patients with rheumatoid arthritis. *Int Immunol* 2001;13:559-65.